Biocon Biologics & Voluntis Collaboration on Digital Therapeutics
Biocon Biologics & Voluntis collaboration on digital therapeutics for diabetes patients
To develop and distribute innovative digital therapeutics for supporting people with diabetes on biologics therapy, the subsidiary of Biocon Ltd., Biocon Biologics India Limited announced a global collaboration agreement with Voluntis on Tuesday.
Biocon Biologics said in a statement that, ‘Insulia’, a U.S. Food and Drug Administration-cleared and CE-marked, digital therapeutic product, will be to offer to type 2 diabetes patients, across several markets in the world through the licensing agreement between Malaysian subsidiary Biocon Sdn. Bhd. and Voluntis.
People with diabetes will be able to self-manage their condition and healthcare teams can remotely monitor progress as Insulia provides automated insulin dose recommendations.
Digital therapeutics created by Voluntis empowers people suffering from chronic conditions to self- manage their treatment every day.
Biocon Biologics CEO and Managing Director, Christiane Hamacher said, “We believe that patient outcomes can be improved and costs to healthcare systems can be reduced in the long term by pairing our products with a digital therapeutic solution. Through innovative solutions, we remain committed to impacting patients’ lives.”
To provide automated titration recommendations for all types of basal insulin, state
, Insulia is the first digital therapeutic with regulatory clearance, according to Biocon Biologics.CEO of Voluntis, Pierre Leurent said, “This collaboration illustrates digital therapeutics’ growing importance as part of the new standards of care, and will help patients around the globe achieve optimal outcomes on their insulin journey.”
Biocon has developed affordable biosimilars, novel biologics, and complex APIs and is an innovation-led fully integrated biopharmaceutical company in India. Voluntis operates as a medical software company and innovates healthcare solutions by embedding connectivity in therapeutics and medical intelligence in software. The Company serves patients in France and the United States.
Source
Biocon Biologics Collaborates With Voluntis For Digital Therapeutics, Biocon Biologics & Voluntis Collaboration
